Earnings History Data for Mirati Therapeutics, Inc. (MRTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
28-02-2023	AH	4:10 PM ET (Feb 28)	MRTX	Mirati Therapeutics, Inc.	2,650	-3.51	-3.74	-3.72	Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M [2/28/2023 4:41 PM]	44.97	-0.87 (-1.90%)	46.75	0.91 (1.99%)	32.96 - 101.30	904,720	850,000	149,465
Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M [2/28/2023 4:41 PM]
08-11-2022	AH	4:00 PM ET (Nov 8)	MRTX	Mirati Therapeutics, Inc.	3,520	-3.09	-3.46	-1.55	Mirati Therapeutics GAAP EPS of -$3.09 beats by $0.40, revenue of $5.4M beats by $4.03M [11/8/2022 4:24 PM]	62.01	2.57 (4.32%)	59.44	0.0 (0.00%)	32.96 - 175.50	1,281,054	700,000	2,947
Mirati Therapeutics GAAP EPS of -$3.09 beats by $0.40, revenue of $5.4M beats by $4.03M [11/8/2022 4:24 PM] Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors [Nov-07-22 08:15AM] Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates [Nov-08-22 04:10PM] Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team [Nov-08-22 04:05PM]
03-08-2022	AH	4:00 PM ET (Aug 3)	MRTX	Mirati Therapeutics, Inc.	3,770	-3.18	-3.53	-3.23	Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.32, revenue of $5.36M beats by $4.98M [8/3/2022 4:22 PM]	77.87	6.09 (8.48%)	3.92	-0.40 (-9.26%)	32.96 - 195.99	842,284	1,040,000	51,552
Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.32, revenue of $5.36M beats by $4.98M [8/3/2022 4:22 PM] Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates [Aug-03-22 04:01PM]
04-05-2022	AH	4:00 PM ET (May 4)	MRTX	Mirati Therapeutics	3,430	-3.40	-3.37	0.00	Mirati Therapeutics GAAP EPS of -$3.40 beats by $0.17, revenue of $0.71M beats by $0.53M [5/4/2022 4:41 PM]	62.39	-1.63 (-2.55%)	64.02	0.0 (0.00%)	60.50 - 195.99	989,144	740,000	7,312
Mirati Therapeutics GAAP EPS of -$3.40 beats by $0.17, revenue of $0.71M beats by $0.53M [5/4/2022 4:41 PM] Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates [May-04-22 04:01PM]
28-02-2022	AH	4:00 PM ET (Feb 28)	MRTX	Mirati Therapeutics, Inc.	4,860	-3.72	-3.01	-2.08		90.18	1.89 (2.14%)	88.29	0.0 (0.00%)	81.54 - 207.07	618,287	1,110,000	185,327
Is a Surprise Coming for Mirati (MRTX) This Earnings Season? [Feb-25-22 08:34AM] Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates [Feb-28-22 04:01PM] Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates [Mar-01-22 07:52AM]
08-11-2021	AH	4:15 PM ET (Nov 8)	MRTX	Mirati Therapeutics, Inc.	8,640	-1.55	-2.87	-1.96	Mirati Therapeutics EPS beats by $1.47, beats on revenue [11/8/2021 4:06 PM]	168.04	8.13 (5.08%)	170.00	10.09 (6.31%)	131.47 - 249.42	702,490	460,000	15,682
Mirati Therapeutics EPS beats by $1.47, beats on revenue [11/8/2021 4:06 PM] Mirati Therapeutics to raise $500M in stock offering [11/9/2021 4:41 PM] SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX [Nov-05-21 05:15PM] Is Mirati Therapeutics (MRTX) A Smart Long-Term Buy? [Nov-08-21 11:11AM] Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates [Nov-08-21 04:01PM] Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates [Nov-08-21 05:25PM] Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference [Nov-09-21 09:00AM] Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing [Nov-09-21 11:00AM] Mirati Therapeutics Announces Proposed Public Offering of Common Stock [Nov-09-21 04:23PM]
06-05-2021	AH	4:15 PM ET (May 6)	MRTX	Mirati Therapeutics, Inc.	7,980	-2.67	-2.13	-2.02	Mirati Therapeutics EPS misses by $0.54 [5/6/2021 5:24 PM]	144.00	-6.77 (-4.49%)	150.77	0.0 (0.00%)	91.90 - 249.42	1,672,399	780,000	370,202
Mirati Therapeutics EPS misses by $0.54 [5/6/2021 5:24 PM]
04-11-2020	AH		MRTX	Mirati Therapeutics, Inc.	9,626	-1.96	-2.04	0.00	Mirati Therapeutics EPS beats by $0.07 [11/4/2020 5:46 PM]	236.36	1.68 (0.72%)	234.68	0.0 (0.00%)	66.01 - 240.58	330,488	986,485	15,910